AN2 Therapeutics (ANTX) Cash from Financing Activities (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Cash from Financing Activities data on file, last reported at $37.3 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 57329.23% year-over-year to $37.3 million in Q1 2026; TTM through Mar 2026 was $37.4 million, a 42373.86% increase from a year earlier, with the FY2025 full-year figure at $113000.0, down 69.62% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $37.3 million, up from $48000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for ANTX reached as high as $66.1 million in Q3 2023 and fell as low as -$321000.0 in Q4 2023.
• Historically, Cash from Financing Activities has averaged $16.1 million across 5 years, with a median of $274000.0 in 2023.
• Across the five-year window, Cash from Financing Activities soared 660760.0% in 2023 and tumbled 99.97% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at -$10000.0 in 2022, then slumped by 3110.0% to -$321000.0 in 2023, then jumped by 107.17% to $23000.0 in 2024, then surged by 108.7% to $48000.0 in 2025, then jumped by 77668.75% to $37.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $37.3 million in Q1 2026, $48000.0 in Q3 2025, and $65000.0 in Q1 2025.